section name header

Pronunciation

po-sa-KON-a-zole

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: triazoles

Indications

REMS


Action

  • Blocks ergosterol synthesis, a major component of fungal plasma membrane.
Therapeutic effects:
  • Fungistatic/fungicidal action against susceptible fungi.

Spectrum:

Pharmacokinetics

Absorption: Well absorbed following oral administration; absorption is optimized by food; IV administration results in complete bioavailability.

Distribution: Extensive extravascular distribution and penetration into body tissues.

Protein Binding: >98%.

Metabolism/Excretion: Some metabolism via UDP glucuronidation; 66% eliminated unchanged in feces, 13% in urine (mostly as metabolites).

Half-Life: 35 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
PO (suspension)unknown3–5 hr8 hr
PO-ERunknown4–5 hr24 hr
IVunknown2 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Treatment of Invasive Aspergillosis

Prophylaxis of Invasive Aspergillus and Candida Infections

Treatment of Oropharyngeal Candidiasis

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Noxafil

Canadian Brand Names

Posanol